GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Research & Development

Zhaoke Ophthalmology (HKSE:06622) Research & Development : HK$236.35 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Zhaoke Ophthalmology's Research & Development for the six months ended in Jun. 2024 was HK$96.67 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was HK$236.35 Mil.

Zhaoke Ophthalmology Research & Development Historical Data

The historical data trend for Zhaoke Ophthalmology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology Research & Development Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
103.94 96.94 269.45 331.03 364.28

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 118.31 218.32 224.60 139.68 96.67

Zhaoke Ophthalmology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$236.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhaoke Ophthalmology  (HKSE:06622) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zhaoke Ophthalmology Research & Development Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Research & Development
Comparable Companies
HKSE:01873 HKSE:06978 HKSE:02496 HKSE:01672 HKSE:02181 HKSE:01244 HKSE:02256 HKSE:02137 HKSE:02616 HKSE:06628 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Website
https://www.zkoph.com
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Executives
Gic Private Limited 2201 Interest of corporation controlled by you
Mak Siu Hang Viola 2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd 2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd 2101 Beneficial owner
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Fidelity China Special Situations Plc 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Vms Holdings Limited 2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p. 2201 Interest of corporation controlled by you

Zhaoke Ophthalmology Headlines

No Headlines